Compare BioNano Genomics Inc (BNGO) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Oatly Group AB - ADR — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Oatly Group AB - ADR trades at $12.93 (market cap $415.98M). The key difference: Oatly Group AB - ADR is far larger — about 30.5× BioNano Genomics Inc's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | OTLY | |
|---|---|---|
Market Cap | $13.66M | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $18.54 |
52-Week Low | $1.06 | $8.03 |
Enterprise Value | $16.26M | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Oatly (OTLY) trades at $13.23, up 0.84% today, with a bullish technical signal supported by moving averages and RSI. The company reported Q2 2026 revenue of $240.1 million, beating expectations, and raised its full-year outlook. However, it remains unprofitable with a net income margin of -13.81% and negative cash flow. Analyst sentiment is mixed with 44% buy ratings, 50% hold, and 6% sell.
Outlook hinges on revenue growth and margin improvements, but risks include high debt, persistent cash burn, and delayed profitability. The stock offers speculative upside if operational turnaround accelerates, yet investors face significant financial stability concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
